Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Saqib Islam
|
| gptkbp:collaboratesWith |
gptkb:Pfizer
gptkb:Janssen_Biotech GlaxoSmithKline |
| gptkbp:developsDrug |
Mirdametinib
Nirogacestat |
| gptkbp:focusesOn |
oncology
rare diseases |
| gptkbp:foundedYear |
2017
|
| gptkbp:founder |
gptkb:Pfizer
|
| gptkbp:headquartersLocation |
gptkb:Stamford,_Connecticut,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
SpringWorks Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
Mirdametinib
Nirogacestat |
| gptkbp:numberOfEmployees |
approximately 200 (2023)
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:specializesIn |
targeted therapies
genetically defined cancers rare tumor types |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
SWTX
|
| gptkbp:website |
https://www.springworkstx.com/
|
| gptkbp:bfsParent |
gptkb:Stephen_Squinto
|
| gptkbp:bfsLayer |
7
|